OSE2101 (TEDOPI) is a neo-epitope based vaccine designed to stimulate the immune system to fight against ovarian cancer cells. It works by teaching the body’s immune system to recognize and attack specific markers found on cancer cells.

Pembrolizumab is an immunotherapy medication that belongs to a group called PD-1 inhibitors. It works by helping the immune system fight cancer cells. This medication blocks certain proteins that can prevent the immune system from attacking cancer cells effectively.

Best supportive care is not a medication but rather a combination of treatments and care measures aimed at improving the quality of life of cancer patients. It includes managing symptoms, providing pain relief, and addressing other health concerns that may arise during cancer treatment.

Platinum-sensitive recurrent ovarian cancer – A form of ovarian cancer that returns after a period of remission following initial platinum-based chemotherapy treatment. The cancer is considered platinum-sensitive when it recurs more than six months after completing the initial platinum-based therapy. This condition develops when cancer cells begin to grow again in or around the ovaries, fallopian tubes, or nearby areas in the abdomen. The disease typically follows a pattern of remission and recurrence, where periods of cancer growth alternate with periods of response to treatment. It affects the female reproductive system and can spread to other parts of the body over time.